MilliporeSigma

Recurrent epithelial ovarian cancer: an update on treatment.

Oncology (Williston Park, N.Y.) (2013-06-21)
Olivia W Foley, J Alejandro Rauh-Hain, Marcela G del Carmen
ABSTRACT

An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months. Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.

MATERIALS
Product Number
Brand
Product Description

Doxorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Doxorubicin hydrochloride, suitable for fluorescence, 98.0-102.0% (HPLC)
Sigma-Aldrich
Doxorubicin hydrochloride, 98.0-102.0% (HPLC)